Taysha Gene Therapies (TSHA) Competitors $2.93 -0.01 (-0.34%) Closing price 04:00 PM EasternExtended Trading$2.95 +0.02 (+0.55%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSHA vs. HHH, IBRX, CNTA, ARWR, BLTE, RXRX, BHC, OCUL, AGIO, and DNLIShould you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Howard Hughes (HHH), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Belite Bio (BLTE), Recursion Pharmaceuticals (RXRX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), Agios Pharmaceuticals (AGIO), and Denali Therapeutics (DNLI). Taysha Gene Therapies vs. Its Competitors Howard Hughes ImmunityBio Centessa Pharmaceuticals Arrowhead Pharmaceuticals Belite Bio Recursion Pharmaceuticals Bausch Health Cos Ocular Therapeutix Agios Pharmaceuticals Denali Therapeutics Howard Hughes (NYSE:HHH) and Taysha Gene Therapies (NASDAQ:TSHA) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Which has preferable valuation and earnings, HHH or TSHA? Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHoward Hughes$1.75B2.49$200.55M$4.5716.04Taysha Gene Therapies$8.33M75.50-$89.30M-$0.34-8.62 Does the media prefer HHH or TSHA? In the previous week, Taysha Gene Therapies had 15 more articles in the media than Howard Hughes. MarketBeat recorded 27 mentions for Taysha Gene Therapies and 12 mentions for Howard Hughes. Howard Hughes' average media sentiment score of 1.06 beat Taysha Gene Therapies' score of 0.14 indicating that Howard Hughes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Howard Hughes 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 2 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, HHH or TSHA? Howard Hughes has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Do analysts prefer HHH or TSHA? Howard Hughes currently has a consensus price target of $80.33, indicating a potential upside of 9.61%. Taysha Gene Therapies has a consensus price target of $8.29, indicating a potential upside of 182.79%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Howard Hughes 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of HHH or TSHA? 93.8% of Howard Hughes shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 33.0% of Howard Hughes shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is HHH or TSHA more profitable? Howard Hughes has a net margin of 12.85% compared to Taysha Gene Therapies' net margin of -1,144.97%. Howard Hughes' return on equity of 10.51% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Howard Hughes12.85% 10.51% 3.15% Taysha Gene Therapies -1,144.97%-78.44%-44.82% SummaryHoward Hughes beats Taysha Gene Therapies on 11 of the 16 factors compared between the two stocks. Get Taysha Gene Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSHA vs. The Competition Export to ExcelMetricTaysha Gene TherapiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$628.95M$4.17B$5.70B$9.79BDividend YieldN/A1.23%3.77%4.10%P/E Ratio-8.6211.2230.8625.27Price / Sales75.5013.16403.8888.61Price / CashN/A7.2725.2228.45Price / Book8.373.219.516.00Net Income-$89.30M-$109.62M$3.26B$265.34M7 Day Performance6.16%6.95%4.50%2.79%1 Month Performance14.01%23.05%5.22%1.51%1 Year Performance30.22%36.30%31.92%25.40% Taysha Gene Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSHATaysha Gene Therapies3.483 of 5 stars$2.93-0.3%$8.29+182.8%+30.7%$628.95M$8.33M-8.62180Earnings ReportAnalyst RevisionHHHHoward Hughes2.2677 of 5 stars$70.40-1.0%$80.33+14.1%+2.5%$4.22B$1.75B15.40608News CoverageIBRXImmunityBio2.2592 of 5 stars$2.47+1.2%$12.25+396.0%-36.4%$2.31B$14.74M-5.15590CNTACentessa Pharmaceuticals2.1848 of 5 stars$16.61-2.4%$28.10+69.2%+44.4%$2.27B$6.85M-9.18200News CoverageEarnings ReportAnalyst DowngradeInsider TradeAnalyst RevisionARWRArrowhead Pharmaceuticals4.2049 of 5 stars$17.21+4.8%$43.14+150.7%-9.6%$2.27B$3.55M-13.45400News CoverageInsider TradeAnalyst RevisionBLTEBelite Bio2.5454 of 5 stars$69.50-0.5%$96.67+39.1%+33.4%$2.22BN/A-51.1010Earnings ReportRXRXRecursion Pharmaceuticals2.1378 of 5 stars$5.29-1.3%$7.00+32.3%-14.4%$2.18B$58.84M-2.97400Positive NewsBHCBausch Health Cos4.3075 of 5 stars$6.68+16.1%$9.00+34.8%+45.5%$2.13B$9.63B25.6820,700Positive NewsOptions VolumeHigh Trading VolumeOCULOcular Therapeutix3.8899 of 5 stars$12.56+2.9%$17.20+36.9%+55.6%$2.12B$63.72M-9.81230AGIOAgios Pharmaceuticals4.281 of 5 stars$35.10-1.8%$56.33+60.5%-17.8%$2.08B$36.50M3.19390DNLIDenali Therapeutics4.141 of 5 stars$13.91-0.3%$33.85+143.3%-36.1%$2.03B$330.53M-5.21430Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies HHH Alternatives IBRX Alternatives CNTA Alternatives ARWR Alternatives BLTE Alternatives RXRX Alternatives BHC Alternatives OCUL Alternatives AGIO Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSHA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access